Lipid conjugates in the treatment of bronchitis
AssigneeYissum Research Development Company
InventorSaul YEDGAR
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating, suppressing, inhibiting, or preventing bronchitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
Claims20
A method of treating or preventing bronchitis in a subject, comprising the step of administering to said subject a composition comprising a compound represented by the structure of the general formula (I):
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- X is glycosaminoglycan, alginate, carboxymethylcellulose, or polygeline;
- and
- n is a number from 1 to 1,000;
- wherein if Y is nothing the phosphatidylethanolamine is directly linked to X via an amide bond and if Y is a spacer, said spacer is directly linked to X via an amide or an esteric bond and to said phosphatidylethanolamine via an amide bond.
A method for ameliorating broncho constriction in a subject, comprising the step of subjecting said subject to a composition comprising a compound represented by the structure of the general formula (I):
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- X is glycosaminoglycan, alginate, carboxymethylcellulose, or polygeline;
- and
- n is a number from 1 to 1,000;
- wherein if Y is nothing the phosphatidylethanolamine is directly linked to X via an amide bond and if Y is a spacer, said spacer is directly linked to X via an amide or an esteric bond and to said phosphatidylethanolamine via an amide bond.
A method for inhibiting contraction of a muscle tissue, comprising the step of subjecting said muscle tissue to a composition comprising a compound represented by the structure of the general formula (I):
- wherein
- R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- X is glycosaminoglycan, alginate, carboxymethylcellulose, or polygeline;
- and
- n is a number from 1 to 1,000;
- wherein if Y is nothing the phosphatidylethanolamine is directly linked to X via an amide bond and if Y is a spacer, said spacer is directly linked to X via an amide or an esteric bond and to said phosphatidylethanolamine via an amide bond.
Dependencies are inferred from the claim text.